Advanced Linker Payload Solutions

03rd July 2024

At the heart of an effective antibody-drug conjugate (ADC) is the linker payload architecture; a critical component that directly influences the therapeutic efficacy and safety of the drug.

Effective linkers are engineered to be stable in the bloodstream but to release the drug payload once inside the tumor environment. This controlled release is crucial for maximizing the therapeutic window and reducing systemic toxicity.

At Abzena, we specialize in the strategic integration of monoclonal antibodies (mAbs) with meticulously designed linkers and payloads to enhance clinical outcomes.

Our expertise encompasses:

  • Precision Engineering
  • Targeted Delivery
  • Custom Solutions
  • Innovative Linker Technology
  • Robust Payload Options

We not only provide tailor-made solutions but also ensure that each component of the ADC—from mAbs to linkers to payloads—is designed to meet the highest standards of safety and effectiveness.

Click here to access our linker payload info sheet to discover how our expert team, technologies, and proprietary solutions can enhance your bioconjugate today.